MicroRNA 520a (miR-520a)

MicroRNA 520a (miR-520a) is a short, non-coding RNA molecule that plays a key regulatory role in gene expression by binding to complementary sequences on target messenger RNAs (mRNAs), leading to translational repression or degradation of these target transcripts[2]. miR-520a is transcribed as part of a primary transcript processed by Drosha and Dicer enzymes, yielding a mature functional microRNA that can become incorporated into the RNA-induced silencing complex (RISC)[2]. It is recognized as a tumor suppressor in multiple cancers, including non-small cell lung cancer and breast cancer, where its downregulation is associated with increased cell proliferation, migration, and invasion[1][3]. miR-520a exerts its function in part by suppressing oncogenic pathways such as the Wnt/β-catenin, NF-κB, and TGF-β signaling pathways through direct targeting of key mRNAs, including RRM2, RELA, and TGFBR2[1][3]. MIR520A is catalogued in standard gene databases such as GeneCards, HGNC, and NCBI Gene, which report its association with several disease states such as Hodgkin's lymphoma and pre-eclampsia[2]. No direct approved drugs are known to specifically interact with miR-520a, but modulation of its expression is considered a potential therapeutic strategy in gene-based cancer therapy[1][3].

Other names

hsa-miR-520aMIRN520AMIR520Ahsa-mir-520a-3pmiR-520a-3p

Targets mRNA (such as RRM2, NF-κB pathway components, TGF-β pathway components) to suppress translation or promote degradation. Inactivates Wnt/β-catenin signaling pathway. Suppresses NF-κB and TGF-β signaling pathways.